Skip to main content

Table 3 Factors associated with 12-month virological success (<500 copies/mL) in the 106 HIV-1-infected children randomised in the ANRS 12206 MONOD study (Abidjan and Ouagadougou, February 2013–February 2015)

From: Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d’Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial

 

Total N = 106

Virological success (<500 copies/mL) N = 89

Virological failure (≥500 copies/mL) N = 17

p value

Country

   

0.83

 Abidjan

71 (67.0)

60 (67.4)

11 (64.7)

 

 Ouagadougou

35 (33.0)

29 (32.6)

6 (35.3)

 

Sex

   

0.81

 Female

59 (55.7)

50 (56.2)

9 (52.9)

 

 Male

47 (44.3)

39 (43.8)

8 (47.1)

 

Treatment arm

   

0.73

 AZT/ABC + 3TC + LPV/r

54 (50.9)

46 (51.7)

8 (47.1)

 

 ABC + 3TC + EFV

52 (49.1)

43 (48.3)

9 (52.9)

 

Main caregiver for children

   

1.00

 Mother main caregiver

88 (83.0)

74 (83.2)

14 (82.4)

 

 Father/other in charge of care

18 (17.0)

15 (16.8)

3 (17.6)

 

Father informed of the child’s HIV status

   

0.30

 No

44 (41.5)

35 (39.3)

9 (52.9)

 

 Yes

62 (58.5)

54 (60.7)

8 (47.1)

 

History of antiretroviral drug exposure

   

0.63

 Prenatal maternal ART

9 (8.5)

7 (7.9)

2 (11.8)

 

 PMTCT only

32 (30.2)

27 (30.3)

5 (29.4)

 

 Postnatal maternal ART only

13 (12.3)

12 (13.5)

1 (5.9)

 

 PMTCT and postnatal maternal ART

10 (9.4)

7 (7.9)

3 (17.6)

 

 No previous exposure to any PMTCT or ART

42 (39.6)

36 (40.4)

6 (35.3)

 

Age at randomisation

   

0.39

 <24 months

41 (38.7)

36 (40.4)

5 (29.4)

 

 ≥24 months

65 (61.3)

53 (59.6)

12 (70.6)

 

WHO clinical stage at randomisation

    

 Stage 1, 2, 3

83 (78.3)

73 (82.0)

10 (58.8)

0.05

 Stage 4

23 (21.7)

16 (18.0)

7 (41.2)

 

Z-score Weight-for-age at ART initiation

   

0.35

 Normal

50 (47.2)

44 (49.4)

6 (35.3)

 

 Moderate

22 (20.7)

19 (21.4)

3 (17.6)

 

 Severe

34 (32.1)

26 (29.2)

8 (47.1)

 

Z-score Height-for-age at ART initiation

   

0.09

 Normal

55 (51.9)

50 (56.2)

5 (29.4)

 

 Moderate

21 (19.8)

15 (16.8)

6 (35.3)

 

 Severe

30 (28.3)

24 (27.0)

6 (35.3)

 

CD4 % at ART initiation

   

0.60

 >35%

13 (12.3)

10 (11.2)

3 (17.6)

 

 25–35%

19 (17.9)

17 (19.1)

2 (11.8)

 

 <25% or missing

74 (69.8)

62 (69.7)

12 (70.6)

 
  1. Data are presented as n (%)
  2. AZT Zidovudine, 3TC Lamivudine, ABC Abacavir, EFV Efavirenz, LPV/r Lopinavir-boosted ritonavir, ART Antiretroviral therapy, PMTCT Prevention of mother-to-child-transmission, WHO World Health Organization. Normal: Z-score ≥ 2 Standard Deviations (SD); Z-score <-2 SD corresponds to moderate malnutrition, being severe form at a Z-score<-3 SD
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us